The U.S. Food and Drug Administration (FDA) cleared Able Medical Devices’ thoracic fixation system called Valkyrie, a breakthrough and fully disposable bioactive sternal plating system. The medical device is intended to stabilize and fixate chest wall fractures as well as sternal reconstructive surgical procedures for patients with normal or poor bone.  Peter J. Didyk, VP & Managing Director of Cardiothoracic and an inventor of the Valkyrie system stated, “The Valkyrie system features the clinically proven performance of rigid fixation combined with the use of novel materials and the benefits of bioactive science to maximize sternal stability and promote bone healing. Its patient-specific design offers intraoperative choices, and its minimal instrumentation focuses on speed, efficiency, and simplicity in the O.R., making it a highly desirable product on the market.”

Read more here.

More on: